What were the main outcomes of the Gilead Sciences 2012 Annual Meeting of Stockholders?

The 2012 Annual Meeting resulted in the election of all 12 director nominees, the ratification of Ernst & Young LLP as the independent auditor, and advisory approval of executive compensation. Importantly, two significant stockholder proposals were approved: one allowing for shareholder action by written consent and another seeking the redemption of the company's 'poison pill' provision.

Did shareholders express concerns about executive compensation?

While the advisory resolution on executive compensation was approved, a significant portion of shareholders voted against it. This indicates some level of dissatisfaction or concern regarding the compensation of Gilead's named executive officers among the shareholder base.

What is the implication of the approved stockholder proposals regarding written consent and the 'poison pill'?

The approval of the proposal for stockholder action by written consent suggests shareholders want more direct avenues to propose and enact corporate changes outside of annual meetings. The approved proposal to address the 'poison pill' indicates a shareholder desire for greater control over potential takeover defenses and potentially a preference for plans that are subject to shareholder vote.

How many shares were represented at the meeting, and did it constitute a quorum?

Yes, a quorum was established. Out of 758,070,530 shares of common stock entitled to vote, 641,235,008 shares were represented either in person or by proxy, which was sufficient to constitute a quorum for the meeting.

GILD 8-K: Shareholder Matters

Summary

This Form 8-K filing by Gilead Sciences, Inc. reports the results of its 2012 Annual Meeting of Stockholders held on May 10, 2012. The primary focus for investors is the outcome of several key votes that took place at the meeting. All proposed director nominees were elected with substantial support, indicating continued confidence in the current board leadership. Furthermore, the company's independent registered public accounting firm for 2012, Ernst & Young LLP, was ratified, which is a routine but important procedural item for financial oversight. Notably, the filing also details the approval of two significant stockholder proposals: one allowing for stockholder action by written consent, and another requesting the redemption of Gilead's "poison pill" shareholder rights plan unless it is put to a stockholder vote. While executive compensation was approved on an advisory basis, the passage of these two governance-related proposals suggests increased shareholder activism and a desire for enhanced corporate governance flexibility and direct shareholder influence. Investors should monitor Gilead's subsequent actions in response to these approved proposals.

Key Highlights

1All 12 director nominees were successfully elected to serve for the ensuing year, receiving significant "For" votes.
2Ernst & Young LLP was ratified as Gilead's independent registered public accounting firm for the fiscal year ending December 31, 2012.
3An advisory resolution approving the compensation of Gilead's named executive officers passed, though with a notable number of "Against" votes.
4A stockholder proposal to permit stockholder action by written consent was approved.
5A stockholder proposal requesting the redemption of Gilead's "poison pill" unless subject to a stockholder vote was also approved.
6A substantial majority of voting shares were represented at the meeting, establishing a quorum.
7The "Broker Non-Votes" were consistent across most proposals, particularly for director elections and executive compensation.

GILEAD SCIENCES, INC. 8-K Report, Shareholder Vote Results (May 14, 2012)

Summary

Key Highlights

Frequently Asked Questions